My research interests primarily focus on breast cancer, lung cancer and early drug development.
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. JAMA Oncol (2019). PMID: 31465093
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med (2018) 379(22):2108-2121. PMID: 30345906
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol (2019) 5(1):74-82. PMID: 30242306
Cancer Immune Therapy
I lead the cancer immunotherapy group at Barts with Professor Thomas Powles, overseeing clinical and translational research on immune checkpoint inhibitors and other immune strategies. The group currently runs more than 10 early clinical trials of single agent or combination cancer immunotherapy treatments, focusing on breast, genitourinary and thoracic cancers.
We are now researching epigenetic 'signatures' of different cancers in order to treat patients with the right medicine for their specific disease. We focus on the role of epigenetics in therapeutic resistance. The aim is to match medicines to patients and reduce the number of patients needlessly subjected to uncomfortable side effects. During this genetic and epigenetic mapping, we also aim to find new cancer-specific targets for drug development.
Novel DNA Damage and Stability Biomarkers and Therapeutic Targets
Over the next 5 years, a variety of novel DDR and chromatin maintenance mechanisms will be validated and, in collaboration with the newly appointed Chairs in Drug Discovery and Medicinal Chemistry, potential inhibitors for synthetic lethality strategies will be identified.
Trials Targeting Therapeutic Resistance
Two international window-of-opportunity trials that Professor Schmid leads focus on establishing the role of targeting the androgen receptor (AR) in early breast cancer, using the novel anti-androgen Enzalutamide:
I also lead a national clinical trial that investigates whether the addition of the HSP27-targeting antisensce oligoneucleotide Apatorsen to chemotherapy can improve the outcome of patients with squamous cell lung cancers.
These trials are supported by NIHR and CRUK funding to the Barts/Brighton Experimental Cancer Medicine Centre. UK recruitment is also supported by the NIHR Cancer Research Network and the UK Experimental Cancer Medicine Centre network.
Our international collaborative group studies circulating biomarkers for screening, diagnosis, patient management and surveillance of breast cancers. The programme includes:
Pembrolizumab for Early Triple-Negative Breast Cancer. Reply Schmid P, Dent R, O'Shaughnessy J The New England journal of medicine (2020) 382(7) e108
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer Adams S, Diéras V, Barrios CH et al. Annals of Oncology (2020) 31(7) 582-589
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study Schmid P, Salgado R, Park YH et al. Annals of Oncology (2020) 31(7) 569-581
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer Rugo HS, Bardia A, Tolaney SM et al. Future Oncology (2020) 16(7) 705-712
Enhancing global access to cancer medicines Cortes J, Perez-García JM, Llombart-Cussac A et al. CA Cancer Journal for Clinicians (2020) 70(7) 105-124
Pembrolizumab for early triple-negative breast cancer Schmid P, Cortes J, Pusztai L et al. New England Journal of Medicine (2020) 382(7) 810-821
Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial Schmid P, Abraham J, Chan S et al. Journal of Clinical Oncology (2020) 38(7) 423-433
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial Schmid P, Rugo HS, Adams S et al. The Lancet Oncology (2020) 21(7) 44-59
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women with Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial Schmid P, Zaiss M, Harper-Wynne C et al. JAMA Oncology (2019) 5(7) 1556-1563
IMpassion132 Phase III trial: Atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer Cortés J, André F, Gonçalves A et al. Future Oncology (2019) 15(7) 1951-1961For additional publications, please click here